PFS
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Paul G Richardson, Aurore Perrot, Joseph Mikhael, Thomas Martin, Meral Beksac, Ivan Spicka, Marcelo Capra, Mattia D'Agostino, Pieter Sonneveld, Kamlesh Bisht, Taro Fukao, Rick Zhang, Keisuke Tada, Christina Tekle, Sandrine Macé, Zandra Klippel, Helgi van de Velde, Philippe Moreau
Blood Cancer J 14(1) 209
The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab-pomalidomide-dexamethasone vs. pomalidomide-dexamethasone) and IKEMA (isatuximab-carfilzomib-dexamethasone vs. carfilzomib-dexamethasone) studies provide large datasets for retrospectively validating the prognostic value of the R2-ISS in relapsed/refractory multiple myeloma. Of 609 pooled patients, 68 (11.2%) were reclassified as R2-ISS stage I, 136 (22.3%) as R2-ISS stage II, 204 (33.5%) as R2-ISS stage III, 55 (9.0%) as stage IV, and 146 (24.0%) "Not classified". Median progression-free survival was shorter among those reclassified as R2-ISS stage II (HR 1.52, 95% CI 0.979-2.358), stage III (HR 2.59, 95% CI 1.709-3.923), and stage IV (HR 3.51, 95% CI 2.124-5.784) versus stage I. Adding isatuximab led to longer progression-free survival versus doublet therapy (adjusted HR 0.544 [95% CI 0.436-0.680]), with a consistent treatment effect observed across all R2-ISS stages. This is the first study to validate the R2-ISS with novel agents, including anti-CD38 monoclonal antibodies, and to show that R2-ISS, as a prognostic scoring system, can be applied to patients with relapsed/refractory multiple myeloma.
3 个 Figure · 7 个 KM 面板
Fig. 2. Pooled data from ICARIA-MM and IKEMA. A validation curves showing progression-free survival by R2-ISS stage. B hazard ratios of progression-free survival by subgroups with individual risk factors. CI confidence interval, HR hazard ratio, ISS International Staging System, LDH lactate dehydrogenase, NC not calculable, PFS progression-free survival, R2-ISS Second Revision of the International Staging System, ULN upper limit of normal.
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3. Pooled data from ICARIA-MM and IKEMA. A validation curves showing overall survival by R2-ISS stage. B hazard ratios of overall survival by subgroups with individual risk factors. CI confidence interval, HR hazard ratio, ISS International Staging System, LDH lactate dehydrogenase, NC not calculable, OS overall survival, R2-ISS Second Revision of the International Staging System, ULN upper limit of normal.
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 Progression-free survival (Isa-based triplet vs. doublet), by R2-ISS stage (pooled data from ICARIA-MM and IKEMA based on disease assessment by the independent response committees). CI confidence interval, HR hazard ratio, Isa-Kd isatuximab–carfilzomib–dexamethasone, Isa-Pd isatuximab–pomalidomide–dexamethasone, PFS progression-free survival, R2-ISS Second Revision of the International Staging System.
Fig. 4 · Panel Stage_I
Panel Stage_I 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel Stage_II
Panel Stage_II 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel Stage_III
Panel Stage_III 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel Stage_IV
Panel Stage_IV 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel Not_classified
Panel Not_classified 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。